There is a need for a cohesive policy to be formulated, keeping in mind all stakeholders, so that innovative pharma companies are rewarded and at the same time prices are controlled for the Indian population. Though easier said than done, a joint solution could be the only way out. Currently, the urgency for formulating an alternative mechanism other than compulsory licensing for reducing prices in developing country such as India, however, remain relatively ignored.

It goes without saying that the verdict in the Glivec case will be an important one, having the potential to impact the way big pharma looks at India. India as an emerging market remains and will continue to remain as a significant part of big pharma's plans, irrespective of these decisions. However, the degree of their involvement will be defined by nature of the upcoming verdicts. For that, pharma companies worldwide seek a clarity about the Indian patent laws.